Question

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

no comments0

Total Forecasters25

Community Prediction

43%

(35% - 47%)

Make a Prediction

50%

community: 43%

No key factors yetAdd some that might influence this forecast.

Add key factor

Authors:

casens

Opened:

Nov 24, 2021

Closes:

Dec 31, 2026

Scheduled resolution:

Jan 1, 2027

Spot Scoring Time:

Nov 26, 2021

Health & Pandemics

Food and Drug Administration

New once-a-month drug could treat diabetes and obesity, scientists say

Independent•Jun 24, 2025

Experimental drug helps patients lose nearly a quarter of body weight in early trials

FOX News•Jun 24, 2025

Monthly weight loss drug helps people lose 20% of body weight, trial finds

NBC•Jun 24, 2025

Learn more about Metaculus NewsMatch

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

63%